Toxicogenomics in predictive toxicology in drug development

Chemistry and Biology

Volumn 11, Issue 2, 2004, Pages 161-171

  Suter, Laura ^a   Babiss, Lee E ^b   Wheeldon, Eric B ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 1542380037     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2004.02.003     Document Type: Review

References (65)

1. Watters J.W., McLeod H.L. Cancer pharmacogenomics. current and future applications Biochim. Biophys. Acta. 1603:2003;99-111.
2. Boggs W.M. Toxicogenomics. Genome-Based Assessment of Drug Toxicity:2003;Decision Resources Inc, Waltham, MA.
3. Goodsaid F.M. Genomic biomarkers of toxicity. Curr. Opin. Drug Discov. Dev. 6:2003;41-49.
4. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients. a meta-analysis of prospective studies JAMA. 279:1998;1200-1205.
5. Ulrich R., Friend S.H. Toxicogenomics and drug discovery. will new technologies help us produce better drugs? Nat. Rev. Drug Discov. 1:2002;84-88.
6. Butte A. The use and analysis of microarray data. Nat. Rev. Drug Discov. 1:2002;951-960.
7. Phillips K.A., Veenstra D.L., Oren E., Lee J.K., Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions. a systematic review JAMA. 286:2001;2270-2279.
8. Acuna G., Foernzler D., Leong D., Rabbia M., Smit R., Dorflinger E., Gasser R., Hoh J., Ott J., Borroni E.et al. Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J. 2:2002;327-334.
9. Alvarado I., Wong M.L., Licinio J. Advances in the pharmacogenomics of adverse drug reactions. Pharmacogenomics J. 2:2002;273.
10. Amin R.P., Hamadeh H.K., Bushel P.R., Bennett L., Afshari C.A., Paules R.S. Genomic interrogation of mechanism(s) underlying cellular responses to toxicants. Toxicology. 181:2002;555-563.
11. Bartosiewicz M.J., Jenkins D., Penn S., Emery J., Buckpitt A. Unique gene expression patterns in liver and kidney associated with exposure to chemical toxicants. J. Pharmacol. Exp. Ther. 297:2001;895-905.
12. Bulera S.J., Eddy S.M., Ferguson E., Jatkoe T.A., Reindel J.F., Bleavins M.R., De La Iglesia F.A. RNA expression in the early characterization of hepatotoxicants in Wistar rats by high-density DNA microarrays. Hepatology. 33:2001;1239-1258.
13. Hamadeh H.K., Bushel P.R., Jayadev S., DiSorbo O., Bennett L., Li L., Tennant R., Stoll R., Barrett J.C., Paules R.S.et al. Prediction of compound signature using high density gene expression profiling. Toxicol. Sci. 67:2002;232-240.
14. Morgan K.T. Gene expression analysis reveals chemical-specific profiles. Toxicol. Sci. 67:2002;155-156.
15. Hamadeh H.K., Bushel P.R., Jayadev S., Martin K., DiSorbo O., Sieber S., Bennett L., Tennant R., Stoll R., Barrett J.C.et al. Gene expression analysis reveals chemical-specific profiles. Toxicol. Sci. 67:2002;219-231.
16. Waring J.F., Ciurlionis R., Jolly R.A., Heindel M., Ulrich R.G. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol. Lett. 120:2001;359-368.
17. Huang Q., Dunn R.T. 2nd, Jayadev S., DiSorbo O., Pack F.D., Farr S.B., Stoll R.E., Blanchard K.T. Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol. Sci. 63:2001;196-207.
18. Luhe A., Hildebrand H., Bach U., Dingermann T., Ahr H.J. A new approach to studying ochratoxin A (OTA)-induced nephrotoxicity. expression profiling in vivo and in vitro employing cDNA microarrays Toxicol. Sci. 73:2003;315-328.
19. Aardema M.J., MacGregor J.T. Toxicology and genetic toxicology in the new era of "toxicogenomics" impact of "-omics" technologies Mutat. Res. 499:2002;13-25.
20. Cheng R.Y., Alvord W.G., Powell D., Kasprzak K.S., Anderson L.M. Microarray analysis of altered gene expression in the TM4 Sertoli-like cell line exposed to chromium(III) chloride. Reprod. Toxicol. 16:2002;223-236.
21. Schena M., Shalon D., Davis R.W., Brown P.O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 270:1995;467-470.
22. Lockhart D.J., Dong H., Byrne M.C., Follettie M.T., Gallo M.V., Chee M.S., Mittmann M., Wang C., Kobayashi M., Horton H.et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat. Biotechnol. 14:1996;1675-1680.
23. Young M.B., DiSilvestro M.R., Sendera T.J., Freund J., Kriete A., Magnuson S.R. Analysis of gene expression in carbon tetrachloride-treated rat livers using a novel bioarray technology. Pharmacogenomics J. 3:2003;41-52.
24. Steiner S., Anderson N.L. Expression profiling in toxicology - potentials and limitations. Toxicol. Lett. 112:2000;467-471.
25. Tseng G.C., Oh M.K., Rohlin L., Liao J.C., Wong W.H. Issues in cDNA microarray analysis. quality filtering, channel normalization, models of variations and assessment of gene effects Nucleic Acids Res. 29:2001;2549-2557.
26. Salter A.H., Nilsson K.C. Informatics and multivariate analysis of toxicogenomics data. Curr. Opin. Drug Discov. Dev. 6:2003;117-122.
27. Ruepp S.U., Tonge R.P., Shaw J., Wallis N., Pognan F. Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol. Sci. 65:2002;135-150.
28. Iida M., Anna C.H., Hartis J., Bruno M., Wetmore B., Dubin J.R., Sieber S., Bennett L., Cunningham M.L., Paules R.S.et al. Changes in global gene and protein expression during early mouse liver carcinogenesis induced by non-genotoxic model carcinogens oxazepam and Wyeth-14,643. Carcinogenesis. 24:2003;757-770.
29. Fountoulakis M., de Vera M., Crameri F., Boess F., Gasser R., Albertini S., Suter L. Modulation of gene and protein expression by carbon tetrachloride in the rat liver. Toxicol. Appl. Pharmacol. 183:2002;71-80.
30. Brazma A., Hingamp P., Quackenbush J., Sherlock G., Spellman P., Stoeckert C., Aach J., Ansorge W., Ball C.A., Causton H.C.et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat. Genet. 29:2001;365-371.
31. Cunningham M.L., Bogdanffy M.S., Zacharewski T.R., Hines R.N. Workshop overview. use of genomic data in risk assessment Toxicol. Sci. 73:2003;209-215.
32. Raychaudhuri, S., Stuart, J.M., and Altman, R.B. (2000). Principal components analysis to summarize microarray experiments: application to sporulation time series. Pac. Symp. Biocomput. 455-466.
33. Ambroise C., McLachlan G.J. Selection bias in gene extraction on the basis of microarray gene-expression data. Proc. Natl. Acad. Sci. USA. 99:2002;6562-6566.
34. Liu A., Zhang Y., Gehan E., Clarke R. Block principal component analysis with application to gene microarray data classification. Stat. Med. 21:2002;3465-3474.
35. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA. 95:1998;14863-14868.
36. Schoelkopf B. Advances in Kernel Methods - Support Vector Learning. 1999;MIT Press, Cambridge, MA.
37. Lesko L.J., Salerno R.A., Spear B.B., Anderson D.C., Anderson T., Brazell C., Collins J., Dorner A., Essayan D., Gomez-Manzilla B.et al. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making. report of the first FDA-PWG-PhRMA-DruSafe workshop J. Clin. Pharmacol. 43:2003;342-358.
38. Robinson D., Pettit S., Morgan D.G. Use of genomics in mechanism based risk assessment. Inoue T., Pennie W.D. Toxicogenomics. 2003;194-203 Springer-Verlag, Tokyo.
39. Hamadeh H.K., Knight B.L., Haugen A.C., Sieber S., Amin R.P., Bushel P.R., Stoll R., Blanchard K., Jayadev S., Tennant R.W.et al. Methapyrilene toxicity. anchorage of pathologic observations to gene expression alterations Toxicol. Pathol. 30:2002;470-482.
40. Chu T., Deng S., Wolfinger R., Paules R., Hamadeh H. Cross-site comparison of gene expression data reveals high similarity. Environ. Health Perspect. Toxicogenomic. 112:2004;. in press.
41. Newton R., Aardema M., Aubrecht J. The utility of DNA microarrays for characterizing genotoxicity. Environ. Health Perspect. Toxicogenomic. 112:2004;. in press.
42. Mattes W. Annotation and cross-indexing of array elements on multiple platforms. Environ. Health Perspect. Toxicogenomic. 112:2004;. in press.
43. Mattes W., Pettit S., Sansone S., Bushel P., Waters M. Database development in toxicogenomics. issues and efforts Environ. Health Perspect. Toxicogenomic. 112:2004;. in press.
44. Goodsaid F., Smith R., Rosenblum I. Quantitative PCR deconstruction of discrepancies between results reported by different hybridization platforms. Environ. Health Perspect. Toxicogenomic. 112:2004;. in press.
45. Rosenzweig B., Pine P., Domon O., Morris S., Chen J., Sistare F. Dye bias correction in dual-labeled cDNA microarray gene expression measurements. Environ. Health Perspect. Toxicogenomic. 112:2004;. in press.
46. Amin R., Vickers A., Sistare F., Thompson K., Roman R., Lawton M.et al. Identification of putative gene based markers of renal toxicity. Environ. Health Perspect. Toxicogenomic. 112:2004;. in press.
47. Baker V., Harries H., Waring J., Duggan C., Ni H., Jolly R., Yoon L., Souza A.D., Schmid J., Brown R.et al. Clofibrate-induced gene expression changes in rat liver. a cross-laboratory analysis using membrane cDNA arrays Environ. Health Perspect. Toxicogenomic. 112:2004;. in press.
48. Thompson K., Afshari C., Amin R., Bertram T., Car B., Cunningham M., Kind C., Kramer J., Lawton M., Mirsky M.et al. Identification of platform-independent gene expression markers of cisplatin nephrotoxicity. Environ. Health Perspect. Toxicogenomic. 112:2004;. in press.
49. Ulrich R., Rockett J., Gibson G., Pettit S. Overview of an inter-laboratory collaboration on evaluating the effects model hepatotoxicants on hepatic gene expression. Environ. Health Perspect. Toxicogenomic. 112:2004;. in press.
50. Pennie W., Pettit S., Lord P. Toxicogenomics in risk assessment. an overview of an ILSI HESI collaborative research program Environ. Health Perspect. Toxicogenomic. 112:2004;. in press.
51. Kramer J., Pettit S., Amin R., Bertram T., Car B., Cunningham M., Curtiss S., Davis J., Kind C., Lawton M.et al. Overview on the application of transcription profiling using selected nephrotoxicants for toxicology assessment. Environ. Health Perspect. Toxicogenomic. 112:2004;. in press.
52. Waring J., Ulrich R., Flint N., Morfitt D., Kalkuhl A., Staedtler F., Lawton M., Beekman J., Suter L. Interlaboratory evaluation of rat hepatic gene expression changes induced by methapyrilene. Environ. Health Perspect. Toxicogenomic. 112:2004;. in press.
53. Suter L., Haiker M., de Vera M.C., Albertini S. Effect of two 5-HT6 receptor antagonists on the rat liver. a molecular approach Pharmacogenomics J. 3:2003;320-334.
54. DeRisi J., Penland L., Brown P.O., Bittner M.L., Meltzer P.S., Ray M., Chen Y., Su Y.A., Trent J.M. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat. Genet. 14:1996;457-460.
55. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., Coller H., Loh M.L., Downing J.R., Caligiuri M.A.et al. Molecular classification of cancer. class discovery and class prediction by gene expression monitoring Science. 286:1999;531-537.
56. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X.et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403:2000;503-511.
57. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., Gascoyne R.D., Muller-Hermelink H.K., Smeland E.B., Giltnane J.M.et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346:2002;1937-1947.
58. Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P., Iyer V., Jeffrey S.S., Van de Rijn M., Waltham M.et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24:2000;227-235.
59. Scherf U., Ross D.T., Waltham M., Smith L.H., Lee J.K., Tanabe L., Kohn K.W., Reinhold W.C., Myers T.G., Andrews D.T.et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24:2000;236-244.
60. Weinstein J.N., Myers T.G., O'Connor P.M., Friend S.H., Fornace A.J. Jr., Kohn K.W., Fojo T., Bates S.E., Rubinstein L.V., Anderson N.L.et al. An information-intensive approach to the molecular pharmacology of cancer. Science. 275:1997;343-349.
61. Giordano T.J., Thomas D.G., Kuick R., Lizyness M., Misek D.E., Smith A.L., Sanders D., Aljundi R.T., Gauger P.G., Thompson N.W.et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am. J. Pathol. 162:2003;521-531.
62. Boess F., Kamber M., Romer S., Gasser R., Muller D., Albertini S., Suter L. Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats. possible implications for toxicogenomics use of in vitro systems Toxicol. Sci. 73:2003;386-402.
63. Esbenshade T.A., Kamanna V.S., Newman H.A., Tortorella V., Witiak D.T., Feller D.R. In vivo and in vitro peroxisome proliferation properties of selected clofibrate analogues in the rat. Structure-activity relationships. Biochem. Pharmacol. 40:1990;1263-1274.
64. Frederiksen K.S., Wulf E.M., Wassermann K., Sauerberg P., Fleckner J. Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists. J. Mol. Endocrinol. 30:2003;317-329.
65. Kramer J.A., Blomme E.A., Bunch R.T., Davila J.C., Jackson C.J., Jones P.F., Kolaja K.L., Curtiss S.W. Transcription profiling distinguishes dose-dependent effects in the livers of rats treated with clofibrate. Toxicol. Pathol. 31:2003;417-431.